secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001493152-22-020809
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte appoints independent director John Peter Gutfreund; he and fund invest $10.5M
--------------------------------------------------------------------------------

- John Peter Gutfreund elected independent director effective July 28, 2022; to chair Finance Committee.
- Gutfreund invested $1M in Series A Preferred Stock (1,176.48 shares) in April 2022 registered direct offering.
- Halle Special Situations Fund LLC, affiliated with Gutfreund, purchased ~$9.5M in common stock and warrants in April 2022.
- CEO expects to bring three major products through reimbursement and to market over next four quarters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/0001493152-22-020809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222020809/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-020809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer